Treatment of primary progressive multiple sclerosis (PPMS) with disease-modifying therapies (DMTs) for patients experiencing relapse or with disease activity is linked to a significant reduction of ...
The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...
PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...
PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...
SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...
Investigational vidofludimus calcium missed its primary target in an exploratory phase II study of progressive multiple sclerosis (MS) but showed promising disability-related trends, data from the ...
Findings showed the study met its primary endpoint demonstrating a reduction in disability accumulation with tolebrutinib compared with placebo. Tolebrutinib was found to delay disability progression ...
Verywell Health on MSN
How multiple sclerosis is treated
Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple sclerosis. Beta interferon drugs reduce MS attacks by altering the immune ...
How Does Ocrevus or Ocrevus Zunovo Work in MS? MS happens when your immune system damages the protective covering around the nerves in your brain, called myelin. This affects how your brain ...
Sanofi provides update on tolebrutinib in primary progressive multiple sclerosis PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to ...
AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results